Story
Rhodiola rosea (Golden root)
Last updated
In one pass Rhodiola is an herb sold to handle stress and fight fatigue, supposedly helping people last longer when they are tired, busy or up late.
Educational content, not medical advice — consult a clinician.
Story path
Chapter 1
What rhodiola is and claims
Rhodiola is an herb sold to handle stress and fight fatigue, supposedly helping people last longer when they are tired, busy or up late. What human trials show is this: in fatigue brought on by stress, a few small trials report less fatigue and better attention. But the samples are all small, most come from teams sharing the same few authors, and no single result has been independently repeated.
It is not a stimulant. As the idea goes, it acts on the body's stress axis: not by crushing the stress hormone, but by making it clock in and out on time, high in the morning when it should be high and falling at night when it should fall. This idea comes mainly from animal experiments and a few human measurements, and it is not settled.
It cannot replace an antidepressant either. If you take an antidepressant, do not stop it on your own and switch to rhodiola. If your mood stays low or you have thoughts of harming yourself, contact a doctor immediately or go to the emergency department.
It is not a stimulant. As the idea goes, it acts on the body's stress axis: not by crushing the stress hormone, but by making it clock in and out on time, high in the morning when it should be high and falling at night when it should fall. This idea comes mainly from animal experiments and a few human measurements, and it is not settled.
It cannot replace an antidepressant either. If you take an antidepressant, do not stop it on your own and switch to rhodiola. If your mood stays low or you have thoughts of harming yourself, contact a doctor immediately or go to the emergency department.
Background · Where the plant grows and its names
Its scientific name is Rhodiola rosea, a perennial herb in the stonecrop family (Crassulaceae), and a typical extreme-environment plant. It grows in alpine rock crevices and tundra at 2000–5000 m, mainly across Siberia, the Altai Mountains, the Carpathians, northern Scandinavia, Alaska and the edges of China's Qinghai-Tibet Plateau. Low oxygen, strong ultraviolet light, huge temperature swings and a growing season of only a few weeks explain why it builds up a set of unusual secondary metabolites (the active compounds described later).Why would a plant stockpile these? Because it cannot run. An animal facing low oxygen, harsh sun or a sudden freeze can move somewhere else; a plant rooted in a rock crevice has to solve the problem where it stands, spending energy that could have gone into growing larger on making molecules that protect it. The active compounds people take were this plant's own emergency chemistry, not something made for humans.
It has many folk names:
In English, golden root, arctic root and rose root (a cut root smells of roses)Russian traditional medicine calls it zolotoi koren (golden root)Vikings in the Nordic countries are said to have used it against fatigue on long sea voyagesChinese medicine also has the name hongjingtian (rhodiola), but what it usually uses is a close relative, Rhodiola crenulata, not rosea, and the chemistry differs a great deal
The word adaptogen is not marketing talk. In the late 1960s, the Soviet pharmacologists Brekhman and Dardymov defined a class of plants that, under stress, pull the body's responses toward the middle, both damping an overreaction and lifting a depleted state, rather than acting as one-way stimulants. Researchers in the field still cite this definition, but mainstream pharmacology does not treat adaptogen as an established drug class, and the word is often hollowed out into a cure-all marketing term.
What does pull toward the middle mean in concrete terms? The same plant turns the response down in someone who is overreacting and lifts it in someone who is already exhausted. It has no fixed direction of turn it up or turn it down, only a direction of return to where it should be. That also foreshadows something you will see later: rhodiola's effects are generally small. Something that only pulls a system toward the middle should not produce a dramatic change in a person already standing in the middle.
Background · Rhodiola's chemical fingerprint
For the chemistry, two groups of molecules matter, because almost every human trial and animal study revolves around them:Rosavins: rosavin, rosin and rosarin, three glycosides known together as rosavins. They occur only in Rhodiola rosea, so they are the chemical fingerprint of genuine rhodiola. If a product label does not state its rosavin content, it is probably not rosea.Salidroside (also called rhodioloside) and its aglycone tyrosol: these occur in several Rhodiola species, so they cannot confirm rosea on their own.
Standardized extracts on the market are often set at about 3% rosavins and 1% salidroside. The one used most in trials is SHR-5, standardized by the Swedish Herbal Institute and usually made as 100 mg or 200 mg tablets. Vitano, Rhodax and Arctic Root are SHR-5 brand names. Mao 2015 (depression), Olsson 2009 (burnout), Darbinyan 2007 (depression) and the earlier trial in night-shift doctors all used it. That matters for reading the evidence: many cheaper rhodiola capsules do not state rosavins at all and may contain Rhodiola crenulata or Rhodiola sachalinensis, whose chemistry is quite different, so what you swallow is not what the trials tested.
The backdrop of this page: an herb that evolved complex chemistry under extreme alpine conditions and has centuries of traditional use across northern Eurasia; modern research that focuses on two groups of molecules, rosavins and salidroside; and a standardized extract, SHR-5, that serves as the bridge between traditional use and human trials.
Chapter 2
How it may act on stress
Rhodiola's mechanism is not one target but three intertwined threads, which is the shared trait of herbs called adaptogens: many pathways, each pushed only a little. First, a caveat: the mechanisms below come mainly from cell and animal experiments, and most have not been measured directly in people.
Thread one: the axis (the hypothalamic–pituitary–adrenal chain of the stress response).
When stress arrives, the hypothalamus releases CRH, the pituitary releases ACTH, and the adrenal cortex releases cortisol, a three-stage amplifier. A short response can save your life (running from danger, for example); left on for a long time, it wears down sleep, digestion and immunity. In animal models, salidroside and rosavins blunt the cortisol surge under stress and make the baseline daily cortisol rhythm (high in the morning, low at night) more orderly. There is one indirect signal in people: Olsson 2009 found that in people with burnout, the cortisol response after waking differed from the placebo group's. The idea is not to crush cortisol but to make it clock in and out on time. This points the same way as ashwagandha, with completely different chemistry.
Thread one: the axis (the hypothalamic–pituitary–adrenal chain of the stress response).
When stress arrives, the hypothalamus releases CRH, the pituitary releases ACTH, and the adrenal cortex releases cortisol, a three-stage amplifier. A short response can save your life (running from danger, for example); left on for a long time, it wears down sleep, digestion and immunity. In animal models, salidroside and rosavins blunt the cortisol surge under stress and make the baseline daily cortisol rhythm (high in the morning, low at night) more orderly. There is one indirect signal in people: Olsson 2009 found that in people with burnout, the cortisol response after waking differed from the placebo group's. The idea is not to crush cortisol but to make it clock in and out on time. This points the same way as ashwagandha, with completely different chemistry.
Mechanism · Monoamines, opioids and mitochondria
Thread two: the monoamine neurotransmitters.Serotonin (), dopamine (DA) and norepinephrine (NE) are all reported to be modulated. The mechanism is not a crude release of transmitters but several light-touch actions stacked together:
Weak inhibition of monoamine oxidase (MAO-A and MAO-B, the enzymes that break these transmitters down), from in vitro data and far below the strength of MAO-inhibitor antidepressants such as phenelzineModulation of monoamine reuptake at presynaptic nerve endingsAn indirect effect on β-endorphin release (through a weak affinity for the μ-opioid receptor)
By the mechanism, these actions together might bring a slight lift in mood and more tolerance for stress, but nothing close to the large release of dopamine and norepinephrine that amphetamine-type drugs cause. So it will not noticeably raise your heart rate the way amphetamine-type ADHD prescriptions do. The distinction matters, and the chapter on marketing claims comes back to it.
Thread three: mitochondria and production.
Animal experiments show that under low oxygen, exercise or cold stress, salidroside makes the mitochondria in skeletal and heart muscle more efficient at producing ATP (the cell's energy currency), tightening the coupling of oxidative phosphorylation and leaking fewer reactive oxygen species (). By the mechanism, this thread fits the anti-fatigue claim; but how much of a person's felt fatigue comes from cells running short of energy is itself unclear.
Mechanism · Why many pathways mean small effects
Besides the three main threads, a few scattered secondary mechanisms turn up: it also modulates nitric oxide (which affects blood vessels and nerve signaling), both scavenges free radicals directly and induces the body's own antioxidant enzymes, and in animals several of its active compounds reach brain tissue. None of these is a main player; they are worth noting and no more.This approach of many pathways, each pushed a little, has an upside: side effects are usually mild. The downside is that the modern pharmacology frame of one target plus a dose-response curve does not fit. You cannot say it works once a certain share of a target is occupied, because several pathways each contribute a little at the same time. This may partly explain why rhodiola's human trials mostly show small positive signals: low-intensity, multi-pathway effects rarely produce dramatic results, and rarely cause serious trouble either.
Rhodiola is not a stimulant. A closer picture is a little oil on several gears of the stress-response system, so the whole machine wears a bit less under long, heavy loads. The picture describes how it is thought to work, not an effect that has been proven.
Chapter 3
Human evidence on fatigue
Line up rhodiola's human trials by date and you see a set of small trials. The signals cluster in stress-related fatigue and short stretches of heavy load, such as night shifts, exam season and burnout. The samples are all small, most trials ran at a single center, and the author teams often overlap. The Hung 2011 systematic review pooled 11 randomized trials and concluded that rhodiola may help physical performance, mental performance and certain mental-health conditions, but that no single study had been independently repeated.
It was compared head to head with the antidepressant sertraline once (Mao 2015): depression scores fell in all three groups, and the differences between them were not statistically significant; the rhodiola group had fewer side effects.
Single doses have also shown a signal (Shevtsov 2003), but effects of this kind are all small.
It was compared head to head with the antidepressant sertraline once (Mao 2015): depression scores fell in all three groups, and the differences between them were not statistically significant; the rhodiola group had fewer side effects.
Single doses have also shown a signal (Shevtsov 2003), but effects of this kind are all small.
Evidence · Night shifts, exam season and burnout
What the key trials measured:Darbinyan 2000 (Phytomedicine, doctors on night duty): 56 young, healthy doctors took 1 tablet of SHR-5 (170 mg) a day during night duty for two weeks, in a randomized, double-blind crossover design (two weeks of rhodiola, two weeks of washout, two weeks of placebo, or the reverse order). The outcome was a fatigue index built from a set of mental tests (associative thinking, short-term memory, calculation, concentration and speed of audio-visual perception). Result: in the first two-week period, the rhodiola group did clearly better than placebo; after the crossover, the same difference was not seen again. No side effects were reported. It modeled exactly the state of sustained heavy load with broken sleep, but a result seen only in the first period is among the hardest kinds to interpret in a crossover design.
Spasov 2000 (Phytomedicine, students at exam time): foreign students at a medical academy took a low dose of SHR-5 for 20 days during their exams, in a randomized, double-blind, placebo-controlled pilot study. The clearest improvements were in physical fitness, mental fatigue and neuromotor tests, and self-rated general well-being was also better; a proofreading test and a tapping test showed no difference. The authors themselves judged that the dose was probably too low. Several later trials reused this design of a short stretch of heavy load.
Shevtsov 2003 (Phytomedicine, a single dose): 161 military cadets aged 19–21 took SHR-5 just once, against a background of fatigue and stress. They were split into a 2-capsule group and a 3-capsule group (a 50% higher dose, corresponding to 370 mg and 555 mg), a placebo group, and a group that took nothing. Both dose groups had a clearly better anti-fatigue index than placebo; the two doses did not differ, and the psychometric tests even leaned slightly toward the lower dose. It is one of the few studies supporting a signal from a single dose, and the effect is small.
Olsson 2009 (Planta Medica, stress-related fatigue, that is, burnout): 60 people aged 20–55 who met the Swedish diagnostic criteria for fatigue syndrome were randomized to SHR-5 at 576 mg a day (288 mg twice a day) or placebo for 28 days. Both groups improved clearly (a placebo effect). Compared with each other, the rhodiola group did better on the Pines burnout scale and on several attention measures, and its cortisol response after waking was different; depression scores and quality of life showed no difference between groups. Burnout is hard to test against placebo, so this is one of only a few such trials, but the sample is still small and it ran at a single center.
Evidence · Versus sertraline, and what reviews say
Mao 2015 (Phytomedicine, mild-to-moderate depression, head to head with sertraline):57 patients with mild-to-moderate major depressive disorder were randomized to three groups: rhodiola (SHR-5, 340–1360 mg a day, stepped up from 1 capsule to 4), sertraline (50–200 mg a day, a commonly used antidepressant) or placebo, for 12 weeks. It was a phase II, proof-of-concept trial.Result: depression scores (HAM-D, the Hamilton Depression Rating Scale) fell in all three groups, but the differences between the groups were not statistically significant. The average HAM-D drop was 8.2 points on sertraline, 5.1 on rhodiola and 4.6 on placebo. Compared with placebo, the for improvement was 1.90 for sertraline and 1.39 for rhodiola, and both crossed 1.Side effects: 63.2% of the sertraline group reported adverse events, against 30.0% on rhodiola and 16.7% on placebo.How to read it: rhodiola's antidepressant effect looked smaller than sertraline's, and so did its side effects. The authors concluded that it may have a more favorable balance of benefit and risk and deserves a larger trial. This trial did not show it beating placebo, let alone replacing an antidepressant.
Darbinyan 2007 (Nordic Journal of Psychiatry, mild-to-moderate depression): 89 patients aged 18–70 with HAM-D scores of 21–31 were assigned to SHR-5 at 340 mg or 680 mg a day, or placebo, for 6 weeks. In both rhodiola groups, overall depression, insomnia, emotional instability and somatization improved, and in the placebo group they did not; there were no serious side effects. The trial shares collaborators with the trials above and has not been independently repeated.
The Hung 2011 systematic review (Phytomedicine): searches ran to July 2009 and found 11 placebo-controlled randomized trials (6 on physical performance, 4 on mental performance, 2 in patients with a diagnosed mental-health condition). Most were of moderate or good methodological quality, and adverse events were few and mild. The conclusion is restrained: rhodiola may benefit physical performance, mental performance and certain mental-health conditions, but every study lacks an independent replication, and more research is needed. Mao 2015, published later, did not change that judgment.
Set among similar herbs:
Ashwagandha: more randomized trials than rhodiola on anxiety and stress, completely different chemistry (withanolides), a similar direction of signal but leaning more toward calmBacopa: research focused on learning and memory, which usually needs about 12 weeks of use before changes show; rhodiola has shown signals over short periods, even after a single dosePanax ginseng: mixed results on fatigue and cognition, with very different chemistry (ginsenosides)
So rhodiola's position is this: in stress-related fatigue and short stretches of heavy load, there are signals from a few small randomized trials, and the certainty of the evidence is low. In mild depression, the only head-to-head comparison by an independent team did not show it beating placebo. Single doses show a signal, but the effect is small. Its evidence falls far short of lifestyle measures such as exercise, sleep and regular meals, and is somewhat more than that behind many products sold as brain-boosting supplements.
Chapter 4
It is not an ADHD drug
Rhodiola marketing on the English-language internet repeats a few false claims. Take them one at a time.
Claim 1: natural Adderall, a natural focus booster.
This line is popular on TikTok, on fitness forums and among productivity influencers. What is wrong with it? Adderall is a mix of amphetamine salts. Its main action is to run the dopamine and norepinephrine transporters in reverse, so concentrations in the synaptic gap shoot up, which is the chemical definition of strong stimulation. Rhodiola's effects on monoamines are light: weak MAO inhibition, mild modulation of reuptake, and an indirect β-endorphin signal. By the mechanism, the two are not in the same league, and equating them is chemically wrong.
More important, ADHD (attention-deficit/hyperactivity disorder) is not ordinary tiredness or a wandering mind. It is a neurodevelopmental psychiatric condition with a genetic basis, differences in brain structure and function, and diagnostic criteria (DSM-5). There are no of rhodiola for treating ADHD. Mixing up I get sleepy in the afternoon with ADHD, and then swapping a stimulant medicine proven for ADHD for an adaptogen, is a mismatch on two levels.
Claim 1: natural Adderall, a natural focus booster.
This line is popular on TikTok, on fitness forums and among productivity influencers. What is wrong with it? Adderall is a mix of amphetamine salts. Its main action is to run the dopamine and norepinephrine transporters in reverse, so concentrations in the synaptic gap shoot up, which is the chemical definition of strong stimulation. Rhodiola's effects on monoamines are light: weak MAO inhibition, mild modulation of reuptake, and an indirect β-endorphin signal. By the mechanism, the two are not in the same league, and equating them is chemically wrong.
More important, ADHD (attention-deficit/hyperactivity disorder) is not ordinary tiredness or a wandering mind. It is a neurodevelopmental psychiatric condition with a genetic basis, differences in brain structure and function, and diagnostic criteria (DSM-5). There are no of rhodiola for treating ADHD. Mixing up I get sleepy in the afternoon with ADHD, and then swapping a stimulant medicine proven for ADHD for an adaptogen, is a mismatch on two levels.
Myth · Pre-workout stimulant and instant brain boost
Claim 2: an ingredient for pre-workout stimulant powders.At some gym supplement counters you will see combined pre-workout powders listing caffeine, theanine, yohimbine and rhodiola, plus energy-drink flavoring. Caffeine and yohimbine do have strong acute stimulant effects, but rhodiola is out of place here: its signal in trials is not sharper alertness but fewer crashes under long, heavy loads. Stuffing an anti-fatigue adaptogen into a scoop that makes your heart race serves a marketing purpose, making the ingredient list look luxurious, and does almost nothing pharmacologically. For a pre-workout lift, 250–400 mg of caffeine is far more direct than 200 mg of rhodiola.
Claim 3: instantly smarter.
The single-dose signal in Shevtsov 2003 is real, but the effect is a small rise in cognitive test scores under fatigue, not 20 extra IQ points. Unless your work involves studying through the night or long stretches of combined physical and mental strain, you will probably not notice any difference in daily life from a single dose, and most of the felt boost will be swallowed by the placebo effect.
Myth · Antidepressant substitute and cure-all
Claim 4: it can replace antidepressants.Read the Mao 2015 data carefully: depression scores fell in all three groups, and the difference between rhodiola and placebo was not statistically significant. Rhodiola did cause far fewer side effects than sertraline, but sertraline's effect was larger, and this was a single trial of 57 people with mild-to-moderate depression; nobody has tested rhodiola in moderate-to-severe depression. The earlier Darbinyan 2007 found a positive result in mild-to-moderate depression that has not been independently repeated. The honest conclusion is that rhodiola is an option for mild depression with little evidence and worth further study, not an substitute, and certainly not plants beat drugs, skip the SSRI.
The pitch stop the drug and switch to an herb can be deadly for people with moderate-to-severe depression. If you take an antidepressant, do not stop it on your own. If your mood stays low or you have thoughts of harming yourself, contact a doctor immediately or go to the emergency department.
Claim 5: an adaptogen is a cure-all.
This one is the sneakiest. Brekhman's definition of an adaptogen has limits: first, it raises non-specific resistance under stress; second, it has a good safety profile; third, it pulls physiological responses toward the middle. It does not mean cures everything. When a product page says rhodiola works for stress, depression, anxiety, fatigue, sexual function, immunity, the heart, aging and brain fog, the definition of an adaptogen has been hollowed out into a cure-all slogan. Every specific claim should match a specific human trial; if it does not, do not buy it.
A side-by-side look at rhodiola versus short-acting caffeine for fatigue:
Caffeine: works in about 30 minutes and lasts 4–6 hours, mainly by blocking adenosine receptors; a strong sense of alertness; rebound fatigue when you stop, and disturbed sleepRhodiola: the single-dose signal shows up in tests taken within a few hours, and it is weak; trials of 2–4 weeks of use found less fatigue; whether there is a rebound after stopping has not been studied systematically; some people report that taking it in the evening affects their sleep, so it is usually taken in the morning
They are different tools. Caffeine handles this afternoon; rhodiola tries to address the steady load of a two-month project. Using the second as a pre-workout stimulant is the wrong tool, and using the first as a long-term plan borrows against your sleep.
Rhodiola has some real small-trial signals in stress-related fatigue, but it is not an ADHD drug, not an acute stimulant, not a substitute for an SSRI and not a cure-all. The core problem with the marketing is that it repackages a low-intensity, multi-pathway, slow-acting herb as a potent, single-target, instant stimulant, and neither chemistry nor clinical data support that.
Chapter 5
Who should try it, and how
Rhodiola fits as an aid during short periods of high pressure or long stretches of heavy load, provided that exercise, sleep and diet are already mostly right and you still feel close to breaking. What is worth trying is a short window, not taking it indefinitely. It is not an ADHD drug, not an acute stimulant, and not a substitute for an antidepressant.
Moderate-to-severe depression, current use of drugs that act on monoamine neurotransmitters, bipolar disorder, pregnancy or breastfeeding: in any of these, do not add it on your own. How to choose a standardized extract, how much and for how long, and why its value ranks behind lifestyle changes are all covered in detail.
Moderate-to-severe depression, current use of drugs that act on monoamine neurotransmitters, bipolar disorder, pregnancy or breastfeeding: in any of these, do not add it on your own. How to choose a standardized extract, how much and for how long, and why its value ranks behind lifestyle changes are all covered in detail.
In practice · Who might try it and who should not
If you want to know whether to try it at all, here is a practical way to think it through based on current evidence. It is not medical advice.Situations worth considering:
1) Long-term work stress with chronic fatigue, where exercise, sleep and diet are already mostly right and you still crash in the afternoon. This is the group where rhodiola's trial signals cluster (the Olsson 2009 burnout trial and the Darbinyan 2000 trial in night-shift doctors), with evidence from a few small randomized trials.
2) Shift work, crossing time zones or a stretch of heavy load, such as doctors and nurses on rotating nights, students in exam season or a push to finish a project at the end of a quarter. The designs of Spasov 2000 and Shevtsov 2003 are closest to these situations; the trials are all small, and the results are not fully consistent (the night-shift trial saw an effect only in its first period).
3) Mild depression, when you are already being treated by a professional and want to discuss an add-on option with fewer side effects with your doctor. The evidence is thin: Darbinyan 2007 had a positive result that has not been independently repeated, and Mao 2015 did not show rhodiola beating placebo. The condition is that you are already inside a treatment plan, not diagnosing yourself and swapping medicine for an herb.
4) Wanting to improve stress tolerance over a short window (2–4 weeks) rather than taking it for life. Most trials ran for 2–12 weeks, not a lifetime.
Situations where it does not fit:
1) Moderate-to-severe depression or anxiety: these need proper psychiatric assessment and treatment (antidepressants and psychotherapy, treatments with stronger evidence), not self-added rhodiola.
2) Using it as a pre-workout stimulant: neither chemistry nor clinical data support it; caffeine is the direct tool.
3) Expecting to become instantly smarter or to gain 20 IQ points: single-dose effects are small, and most of the boost people feel is the placebo effect.
4) Bipolar disorder: because it modulates monoamines, it could in theory trigger hypomania, and data are scarce; people with bipolar disorder should ask a doctor before using any herb with an antidepressant-like mechanism.
5) Taking an , , MAO inhibitor or bupropion: in theory the effects on serotonin () and MAO pathways could add up and raise the risk of serotonin syndrome (an acute reaction to too much serotonin in the body), so at the very least have a pharmacist check.
6) Pregnancy and breastfeeding: data are insufficient, so avoid it to be safe.
In practice · Choosing a product and a dose
If you decide to try it, here is how:Product: the standardized extract SHR-5, or an equivalent product standardized the same way. Vitano, Rhodax, Arctic Root and the SHR-5 product from Nature's Way in Sweden all belong here. Check whether the label states the rosavin content; if it does not, do not buy it.Dose: 200–400 mg a day; most trials used 170–680 mg a day. Start at 200 mg, and if after two weeks you notice nothing and have no side effects, increase to 400 mg.Timing: in the morning (once, or split between morning and midday). Some people report that taking it in the evening affects their sleep.Duration: try it for 4 weeks, then evaluate. If nothing has changed for you, stop; do not keep taking it indefinitely. If it seems to help, some people cycle it, 4 weeks on and 1–2 weeks off, though no trial has compared this with continuous use.How to judge it: do not rely on feel alone. Note your sleep time, a morning energy score (1–10), whether you can get through the afternoon without coffee, and whether weekends still leave you wiped out; a simple diary is more accurate than memory.
On safety, rhodiola's record in trials is fairly clean:
Common side effects: mild stomach upset, headache and insomnia (mostly when taken in the evening), which usually fade within a week or two or improve with a lower doseNo clear liver or kidney toxicity has been reported in trialsNo important drug interactions have been reported; but if you take it with an antidepressant (see the and MAO-inhibitor point above), or you are on an anticoagulant, ask a doctor or pharmacist firstData on long-term use (over 6 months) are insufficient, so by default do not take it continuously for long periods
In practice · Where time and money pay off first
Ranked by where time and money pay off most:Exercise, 150 minutes a week: supported by a large body of research, helpful for fatigue, depression and anxiety, and nearly freeSleep, 7–9 hours: free, but it takes timeCognitive behavioral therapy (, a structured form of psychotherapy): one of the first-line treatments for depression and anxietyA Mediterranean-style or other regular eating pattern: supported by a good deal of research, at moderate costRhodiola: signals from a few small trials, low certainty of evidence, moderate cost; suited to people who have handled everything above and still have leftover symptomsAssorted brain-boosting supplement stacks (, , lion's mane and so on): even less evidence, a lower priority than everything above
Rhodiola is an herb with some real small-trial signals and a decent safety record, suited as an aid in the specific situation of short-term high pressure on top of a long-term load. It does not replace exercise, sleep or psychotherapy, and it is not an ADHD drug, an substitute, a pre-workout stimulant or a cure-all. If you want to try it, use standardized SHR-5, give it a 2–4 week window, judge it objectively and stop if it does nothing. It is a low-risk experiment, but before you start, it is best to have done the things with stronger evidence first.
References · 7
- Panossian, A., Wikman, G., & Sarris, J. (2010). Rosenroot (Rhodiola rosea): traditional use, chemical composition, pharmacology and clinical efficacy. Phytomedicine, 17(7), 481–493. 10.1016/j.phymed.2010.02.002
- Olsson, E. M., von Schéele, B., & Panossian, A. G. (2009). A randomised, double-blind, placebo-controlled, parallel-group study of the standardised extract SHR-5 of the roots of Rhodiola rosea in the treatment of subjects with stress-related fatigue. Planta Medica, 75(2), 105-112. 10.1055/s-0028-1088346
- Darbinyan, V., Aslanyan, G., Amroyan, E., Gabrielyan, E., Malmström, C., & Panossian, A. (2007). Clinical trial of Rhodiola rosea L. extract SHR-5 in the treatment of mild to moderate depression. Nordic Journal of Psychiatry, 61(5), 343–348. 10.1080/08039480701643290
- Spasov, A. A., Wikman, G. K., Mandrikov, V. B., Mironova, I. A., & Neumoin, V. V. (2000). A double-blind, placebo-controlled pilot study of the stimulating and adaptogenic effect of Rhodiola rosea SHR-5 extract on the fatigue of students caused by stress during an examination period with a repeated low-dose regimen. Phytomedicine, 7(2), 85–89. 10.1016/S0944-7113(00)80078-1
- Shevtsov, V. A., Zholus, B. I., Shervarly, V. I., Vol'skij, V. B., Korovin, Y. P., Khristich, M. P., Roslyakova, N. A., & Wikman, G. (2003). A randomized trial of two different doses of a SHR-5 Rhodiola rosea extract versus placebo and control of capacity for mental work. Phytomedicine, 10(2-3), 95–105. 10.1078/094471103321659780
- Mao, J. J., Xie, S. X., Zee, J., Soeller, I., Li, Q. S., Rockwell, K., & Amsterdam, J. D. (2015). Rhodiola rosea versus sertraline for major depressive disorder: a randomized placebo-controlled trial. Phytomedicine, 22(3), 394–399. 10.1016/j.phymed.2015.01.010
- Hung, S. K., Perry, R., & Ernst, E. (2011). The effectiveness and efficacy of Rhodiola rosea L.: a systematic review of randomized clinical trials. Phytomedicine, 18(4), 235-244. Eleven placebo-controlled RCTs met inclusion: 6 on physical performance, 4 on mental performance, 2 in diagnosed mental-health conditions. Methodological quality mostly moderate or good, and only a few mild adverse events. ⚠️ The conclusion is deliberately weak: R. rosea MAY have beneficial effects, but there is a LACK OF INDEPENDENT REPLICATION of the individual studies and more research is warranted. Do not cite this review for consistency of effect — non-replication is its main finding. 10.1016/j.phymed.2010.08.014